• Publications
  • Influence
Isolation and properties of the FSH and LH-releasing hormone.
Abstract LH-releasing hormone (LH-RH) was obtained in apparently a homogeneous state from extracts of pig hypothalami. The LH-RH preparation isolated has FSH-releasing hormone (FSH-RH) activity,Expand
Gonadotropin-Releasing Hormone: One Polypeptide Regulates Secretion of Luteinizing and Follicle-Stimulating Hormones
A polypeptide isolated from porcine hypothalami stimulates the release of both luteinizing hormone and follicle-stimulating hormone from the pituitaries of several species. This polypeptide has beenExpand
Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.
Using animal models of acinar and ductal pancreatic cancer, we investigated the effect of analogs of hypothalamic hormones on tumor growth. In Wistar/Lewis rats bearing the acinar pancreatic tumorExpand
Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.
In the search for selective and long-acting analogs of somatostatin, nearly 200 compounds were synthesized by solid-phase methods, purified, and tested biologically. Among these octapeptides, someExpand
Isolation and properties of porcine thyrotropin-releasing hormone.
Abstract Isolation on a preparative scale of thyrotropin-releasing hormone from porcine hypothalami is described. The yields from two batches of 100,000 and 165,000 hypothalami were 2.8 mg and 4.4Expand
The half-life, metabolism and excretion of tritiated luteinizing hormone-releasing hormone (LH-RH) in man.
ABSTRACT Synthetic 3H-labeled luteinizing hormone-releasing hormone (LH-RH) with a specific activity of 18.3 Ci/mM and the same biological activity as pure porcine LH-RH was used to study theExpand
Investigation of the combination of the agonist D‐Trp‐6‐LH‐RH and the antiandrogen flutamide in the treatment of dunning R‐3327H prostate cancer model
The therapy for the treatment of prostate cancer and other sex‐steroid‐dependent tumors based on agonists of LH‐RH has been made more practical and efficacious by the development of a long‐actingExpand
Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin
BDF female mice inoculated with MXT mammary adenocarcinoma were treated for 30 days with microcapsules of the luteinizing hormone-releasing hormone (LH-RH) agonist D-Trp-6-LH-RH (releasing 25µg/dayExpand
Studies on the Inactivation of Thyrotropin-Releasing Hormone (TRH)∗
Summary Inactivation of porcine thyrotropin-releasing hormone (TRH) by plasma fractions in vitro was determined using mice maintained on a low iodine diet and pre-treated with 5 μCi of 125I and 0.085Expand
Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
  • A. Schally, T. Redding
  • Chemistry, Medicine
  • Proceedings of the National Academy of Sciences…
  • 1 October 1987
The combination of a long-acting delivery system for the agonist [D-Trp6]luteinizing hormone-releasing hormone ([D-Trp6]LH-RH) with modern somatostatin analogs was studied in the Dunning R-3327H ratExpand